Role of lifestyle and oral anti-diabetic agents to prevent type 2 diabetes mellitus and cardiovascular disease. Dahkki Bethel, M, Califf, R

Untitled reply Dahkki Holman, R, Sourij, H, Califf, R

People at increased risk of cardiovascular disease screened for the NAVIGATOR trial frequently have undiagnosed diabetes or impaired glucose tolerance Dahkki Califf, R, Holman, R, Comm, N

Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Dahkki Holman, R, Sourij, H, Califf, R

Randomized clinical trials--removing obstacles. Dahkki Reith, C, Landray, M, Califf, R

Cardiovascular outcome trials of glucose-lowering strategies in type 2 diabetes--Authors' reply. Dahkki Holman, R, Sourij, H, Califf, R

Randomized clinical trials--removing obstacles. Dahkki Reith, C, Landray, M, Califf, R

Rationale and design of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) Dahkki Bethel, M, Green, J, Califf, R, Holman, R

Prediabetes and the risk of diabetes. Dahkki McMurray, J, Haffner, S, Califf, R, Holman, R

Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers for Hypertension on Clinical End Points: A Cohort Study Dahkki Mcmurray, J, Califf, R, Bethel, A, Haffner, S, Holman, R

Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for hypertension on clinical end points: a cohort study. Dahkki McMurray, J, Califf, R, Bethel, A, Haffner, S, Holman, R

Association of non-alcoholic steatothepatitis with components of the metabolic syndrome in 43,509 patients screened for NAVIGATOR Dahkki Bethel, A, Califf, R, McMurray, J, Labed, A, Holman, R, Haffner, S

Cardiologists should care about glucose: most people with CV disease or risk factors have diabetes or significant glycaemic abnormalities. Results of screening over 39,000 subjects... Dahkki McMurray, J, Califf, R, Holman, R, Haffner, S, Lau, M, Pecher, E

Analyses of cancer data from three ezetimibe trials. Dahkki Peto, R, Emberson, J, Landray, M, Baigent, C, Collins, R, Clare, R, Califf, R

Determining the most appropriate components for a composite clinical trial outcome. Dahkki Bethel, M, Holman, R, Haffner, S, Califf, R, Huntsman-Labed, A, Hua, T, McMurray, J

Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance O... Dahkki Califf, R, Boolell, M, Haffner, S, Bethel, M, McMurray, J, Duggal, A, Holman, R

Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established c... Dahkki Green, J, Bethel, M, Paul, S, Ring, A, Kaufman, K, Shapiro, DR, Califf, R, Holman, R

Can delaying the onset of type 2 diabetes be cost-effective? Dahkki Gray, A, Leal, J, Rivero-Arias, O, Reed, S, Li, Y, Schulman, K, Califf, R, Holman, R

Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy. Dahkki Mahaffey, K, Granger, C, Collins, R, O'Connor, C, Ohman, E, Bleich, S, Col, J, Califf, R

Metabolic syndrome and alanine aminotransferase: a global perspective from the NAVIGATOR screening population. Dahkki Bethel, M, Deedwania, P, Levitt, N, Schmitz, O, Huntsman-Labed, A, Califf, R, Haffner, S, Diem, P